Does a fixed-dose regimen of oral apixaban alone safely and effectively treat acute venous thromboembolism compared to conventional therapy?
Patients with acute venous thromboembolism
Oral apixaban (fixed-dose regimen alone)
Conventional therapy
Treatment of acute venous thromboembolism
Oral apixaban is noninferior to conventional therapy for treating acute venous thromboembolism while significantly reducing bleeding risk.
A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Building similarity graph...
Analyzing shared references across papers
Loading...
Giancarlo Agnelli
Harry R. Büller
Alexander T. Cohen
New England Journal of Medicine
McMaster University
Amsterdam UMC Location University of Amsterdam
Pfizer (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Agnelli et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d56c1675589c71d767cb6d — DOI: https://doi.org/10.1056/nejmoa1302507